CGON stock forecast, quote, news & analysis
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer... Show more
CG Oncology, Inc. (CGON) Stock Analysis: Navigating the Path to First BLA Amid High-Impact Clinical Catalysts
Key Takeaways
- CG Oncology (CGON) is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer.
- The stock has traded in a relatively contained range over the past 30 days, with a modest gain of approximately 3%, reflecting a period of consolidation following stronger year-to-date gains.
- Positive Phase 2 CORE-008 Cohort CX data presented in May demonstrated 96% high-grade event-free survival at three months and 92.3% complete response rates in the efficacy evaluable population, reinforcing the clinical profile of cretostimogene.
- Management expects to complete the company's first Biologics License Application (BLA) submission in the fourth quarter of 2026, targeting high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
- Wall Street maintains a broadly positive stance with a consensus "Strong Buy" rating and an average analyst price target of approximately $90, representing significant upside from recent trading levels.
Current Market Snapshot
CG Oncology shares have exhibited relative stability over the past 30 days, gaining roughly 3% as the stock consolidated near the upper end of its recent trading range. The shares closed at $71.40 on August 4, 2026, reflecting a measured advance from approximately $69.26 a month earlier. This period of tempered price action follows a notably stronger run in the preceding months, during which the stock gained roughly 12% over the quarter, driven by positive clinical data, analyst upgrades, and growing clarity around the regulatory pathway for cretostimogene. With a market capitalization near $6.3 billion, CGON trades above its 50-day and 200-day moving averages, though the stock remains below its 52-week high of $77.00. Institutional ownership stands at approximately 26.6%, while a short interest ratio above 12 days suggests a notable bearish contingent that could fuel volatility around upcoming catalysts.
CG Oncology, Inc. (CGON) Business Overview and Competitive Position
CG Oncology is a late-stage clinical biopharmaceutical company headquartered in Dallas, Texas, dedicated to developing and commercializing bladder-sparing therapeutics for patients with bladder cancer. The company's lead product candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy designed to selectively replicate in and destroy bladder cancer cells while activating a systemic anti-tumor immune response. The clinical development program spans two Phase 3 trials — BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC — along with the multi-cohort Phase 2 CORE-008 study evaluating cretostimogene across multiple NMIBC disease states. With over 600 patients treated across its clinical program, a robust $1.1 billion cash position funding operations through 2029, and a first-mover opportunity in a bladder cancer market with significant unmet need, CG Oncology is positioned as one of the more closely watched names in the uro-oncology biotech space.
Recent Developments Driving CGON
Several important developments have shaped investor sentiment around CGON in recent weeks. On May 8, 2026, the company reported first-quarter financial results, posting a net loss of $0.71 per share — wider than the consensus estimate of $0.58 — while quarterly revenue of $1.08 million handily exceeded analyst expectations. More significantly, management provided updated BLA guidance, confirming that submission completion is expected in the fourth quarter of 2026 following alignment discussions with the FDA.
Just one week later, on May 15, CG Oncology unveiled positive first results from the Phase 2 CORE-008 Cohort CX trial at the American Urological Association (AUA) Annual Meeting. The combination of cretostimogene with gemcitabine demonstrated a 96.0% high-grade event-free survival rate at three months and 89.5% at six months, with complete response rates reaching 92.3% in the efficacy evaluable CIS-containing population. Notably, no Grade 3 or higher treatment-related adverse events were reported. The data prompted a wave of analyst reaffirmations, with Truist, UBS, Wedbush, RBC Capital, and H.C. Wainwright all maintaining Buy-equivalent ratings and raising price targets.
On the corporate front, the company strengthened its executive leadership team with the appointment of Jim DeTore as Chief Financial Officer in April. Institutional activity has been mixed, with Wellington Management, T. Rowe Price, and State Street meaningfully increasing their positions in recent quarters, while some insider selling — including director sales by James Mulay and Leonard Post — has attracted attention. The stock's elevated short interest also suggests divergent views on the company's near-term trajectory.
Trending AI Robots
For investors seeking a systematic approach to tracking stocks like CGON, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots actively trading thousands of securities across global markets. Tickeron hosts hundreds of algorithmic trading bots, but only those demonstrating strong recent performance and strategic relevance appear in this featured section. These bots span a wide range of trading strategies — from swing trading and momentum-based approaches to longer-term trend-following models — allowing users to browse bots by asset class, time horizon, and historical track record. The Trending AI Robots page is designed to help traders and investors quickly identify the strategies currently resonating with market conditions without manually sorting through the full bot library.
2026 Outlook and What Investors Should Watch
The remainder of 2026 is set to be eventful for CG Oncology. The nearest major catalyst is the anticipated release of topline data from the Phase 3 PIVOT-006 trial evaluating cretostimogene monotherapy as an adjuvant treatment for intermediate-risk NMIBC, expected in the first half of 2026. This readout represents a high-impact event given the substantially larger addressable patient population in the intermediate-risk setting. Additionally, durability data from the BOND-003 cohorts and CORE-008 Cohort A are expected later in the year. The completion of the company's first BLA submission in the fourth quarter marks the most significant regulatory milestone in CG Oncology's history as a pre-commercial company. Investors should also monitor the upcoming Q2 2026 earnings report, estimated for early August, for updates on BLA progress, PIVOT-006 timing, and cash runway. Key risks include potential clinical setbacks, regulatory delays, competitive developments in the NMIBC space, and the possibility that high short interest could amplify stock price volatility around binary events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CGON's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CGON turned positive on August 07, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in of 27 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 05, 2026. You may want to consider a long position or call options on CGON as a result. In of 43 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in of 136 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CGON moved out of overbought territory on July 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CGON broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CGON entered a downward trend on August 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.435) is normal, around the industry mean (20.281). P/E Ratio (0.000) is within average values for comparable stocks, (25.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.845). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (437.072).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology